ClinicalTrials.gg
Not yet recruitingNCT07858175GREATUpdated Oct 5, 2026

Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies

An observational study in Autoimmune Encephalitis, Anti-NMDAR Encephalitis and Anti-GABABR Encephalitis, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Not yet recruiting at 5 sites in China. Open to participants aged 14 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Observational

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
300
Ages
14 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Autoimmune Diseases of the Nervous System with a site in China — 18 open to participants now, 20 under way, 3 of them phase 3. Autoimmune Diseases of the Nervous System · China.

Planned enrollment
6th of 13
300 · median 300
Started
2026
with 4 others
Observational
13 of 26
9 open now
Primary completion
2028-10
later than 14 of 19 live
Registered
26th of 26
by date
Lead sponsor
2 of 26
Third Affiliated Hospital, Sun Yat-Sen University

Among the 26 studies in Autoimmune Diseases of the Nervous System with a site in China, this one is the 6th largest by planned enrollment of the 13 observational ones that give a count, is one of 5 that started in 2026, is one of 13 observational ones, reaches primary completion later than 14 of the 19 other live ones, and was the 26th registered.

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

Browse Autoimmune Diseases of the Nervous System studies →

Open to participants now

18 of the 26 studies in Autoimmune Diseases of the Nervous System with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.

This study: 14 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Autoimmune Diseases of the Nervous System with a site in China, or all of them as a file.
02

Study summary

This multicenter, blinded, cross-sectional study aims to evaluate the clinical performance of a novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABAB receptor (anti-GABABR) antibodies. A total of 300 participants will be enrolled across four groups: (a) 50 patients with anti-GABABR antibody-positive encephalitis; (b) 100 patients with suspected autoimmune encephalitis and negative anti-neuronal antibody cell-based assay (CBA); (c) 50 patients with non-autoimmune disease (Alzheimer's disease); and (d) 100 patients with anti-NMDAR antibody-positive encephalitis. Residual serum and cerebrospinal fluid samples will be tested using the optimized DAB-TBA. Discordant results between CBA and DAB-TBA will be adjudicated by an independent panel using confirmatory methods (immunoblot, repeat CBA, and clinical follow-up), and inter-reader agreement will be reported. The sensitivity, specificity, and ROC curve of the assay will be evaluated against the reference standard.

Read the detailed description

Anti-GABAB receptor (anti-GABABR) encephalitis is a recognized subtype of autoimmune encephalitis. Antibody detection is essential for diagnosis and differential diagnosis, and cell-based assays (CBA) are the current recommended reference method. The tissue-based assay (TBA) using DAB chromogenic immunohistochemistry offers a widely accessible complement for detecting anti-neuronal antibodies. This study validates the clinical performance of a novel DAB chromogenic TBA developed by Guangzhou KingMed Diagnostics Center. Participants are recruited from neurology departments across multiple centers and enrolled into four groups based on clinical diagnosis and CBA results. Residual serum and CSF samples (no additional sampling) are tested in a blinded manner, and the sensitivity, specificity, and ROC curve of the DAB-TBA for detecting anti-GABABR antibodies are evaluated against the reference standard.

03

Conditions studied

  • Autoimmune Encephalitis
  • Anti-NMDAR Encephalitis
  • Anti-GABABR Encephalitis

Keywords

  • GABABR
  • autoimmune encephalitis
  • DAB
  • tissue-based assay
  • autoantibody
04

Who can participate

Ages eligible
14 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 14-85 years recruited from neurology departments across participating centers, grouped as: (a) anti-GABABR antibody-positive encephalitis; (b) suspected autoimmune encephalitis with negative anti-neuronal antibody CBA; (c) non-autoimmune disease (Alzheimer's disease); (d) anti-NMDAR antibody-positive encephalitis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group a: age 14-85 years; anti-GABABR antibody CBA positive; diagnosed with GABABR antibody encephalitis. Group b: age 14-85 years; suspected encephalitis with acute/subacute onset (\<3 months) and one or more neurological/psychiatric symptoms (e.g. memory impairment, seizures, psychiatric/behavioral abnormalities); anti-neuronal antibody CBA negative; other etiologies reasonably excluded; identifiable address and resident in the region during treatment; willing to provide and comply with follow-up. Group c: age 14-85 years; non-autoimmune disease patients (Alzheimer's disease confirmed by serum/CSF AD biomarker testing). Group d: age 14-85 years; anti-NMDAR antibody CBA positive; diagnosed with NMDAR antibody encephalitis.

Exclusion criteria

Exclusion Criteria:

  1. Residual serum or CSF volume insufficient for DAB-TBA and confirmatory testing.
  2. Sample quality unacceptable (gross hemolysis, lipemia, contamination, or clot).
  3. Freeze-thaw cycles exceeding the predefined limit (specify N).
  4. Key clinical information (final diagnosis, CBA result, or demographic data) unavailable or incomplete.
  5. Sample previously included in this study (repeat sample from the same patient).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group A

    Anti-GABABR antibody-positive encephalitis group (n=50)

  • Group B

    Suspected AE with negative anti-neuronal antibody CBA (n=100)

  • Group C

    Non-autoimmune disease group: Alzheimer's disease (n=50)

  • Group D

    Anti-NMDAR antibody-positive encephalitis group (n=100)

06

What researchers measure

Primary outcomes

  1. Sensitivity of novel DAB chromogenic TBA for detection of anti-GABABR antibodies

    Sensitivity of the novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABABR antibodies, calculated as true positive / (true positive + false negative), using CBA results as the reference standard.

    Time frame: up to 3 months

  2. Specificity of the novel DAB chromogenic TBA for detection of anti-GABABR antibodies

    Specificity of the novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABABR antibodies, calculated as true negative / (true negative + false positive), using CBA results as the reference standard.

    Time frame: up to 3 months

  3. Area under the ROC curve (AUC) of DAB chromogenic TBA for anti-GABABR antibody detection

    ROC curve and AUC value of the novel DAB chromogenic TBA for anti-GABABR antibody detection with CBA as reference standard.

    Time frame: up to 3 months

Secondary outcomes

  1. Cohen's kappa coefficient between DAB-TBA and CBA reference method

    Concordance between the novel DAB chromogenic TBA and the CBA reference method for anti-GABABR antibody detection, quantified by Cohen's kappa coefficient.

    Time frame: up to 3 months

  2. Agreement between serum and CSF detection results by DAB-TBA

    Concordance of DAB chromogenic TBA results between paired serum and CSF samples, expressed as agreement percentage and Cohen's kappa.

    Time frame: up to 3 months

  3. Subgroup detection performance of DAB-TBA

    Sensitivity and specificity of the DAB chromogenic TBA stratified by the four predefined subgroups (anti-GABABR-positive encephalitis, CBA-negative suspected autoimmune encephalitis, non-autoimmune neurological disease, and anti-NMDAR encephalitis).

    Time frame: up to 3 months

07

Study locations

5 sites
08

References and documents

Publications

  • Smith TL, Haven TR, Zuromski LM, Luong K, Clardy SL, Peterson LK. High level of agreement in a fixed vs. live cell-based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting. Front Neurol. 2023 Jul 12;14:1192644. doi: 10.3389/fneur.2023.1192644. eCollection 2023. PubMed 37503513 ↗
  • Spagni G, Gastaldi M, Businaro P, Chemkhi Z, Carrozza C, Mascagna G, Falso S, Scaranzin S, Franciotta D, Evoli A, Damato V. Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm. 2022 Oct 21;10(1):e200038. doi: 10.1212/NXI.0000000000200038. Print 2023 Jan. PubMed 36270951 ↗
  • Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, Gleichman AJ, Balice-Gordon R, Rosenfeld MR, Lynch D, Graus F, Dalmau J. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014 Feb;13(2):167-77. doi: 10.1016/S1474-4422(13)70282-5. Epub 2013 Dec 18. PubMed 24360484 ↗
  • Papi C, Milano C, Arlettaz L, Businaro P, Marmolejo L, Naranjo L, Planaguma J, Martinez-Hernandez E, Armangue T, Guasp M, Ruiz-Garcia R, Aguilar E, Gastaldi M, Iorio R, Gaig C, Saiz A, Sabater L, Graus F, Dalmau JO, Spatola M. Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II): Antibodies to Surface Antigens. Neurol Neuroimmunol Neuroinflamm. 2025 Jul;12(4):e200406. doi: 10.1212/NXI.0000000000200406. Epub 2025 May 20. PubMed 40393020 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared. Aggregated study results will be published in peer-reviewed scientific journals.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858175
Collaborators
Guangzhou KingMed Center for Clinical Lab.Co., Ltd
Responsible party
Wei Qiu (Chief Physician, Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Wei Qiu, MD
Contact
qiuwei120@vip.163.com
+86-15899968330
Yaqing Shu, MD
Contact
shuyaqing@126.com
+86-13724865420
Wei Qiu, MD
principal investigator · Third Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion